On August 7, SBP GROUP rose 3.25% in regular trading, trading at HK$5.09 per share, with turnover of HK$301 million. The rally was driven by a cluster of pipeline catalysts announced over the preceding days.

On August 6, the company's subsidiary Beijing Tide Pharmaceutical received NMPA marketing approval for its second-generation Flurbiprofen Patch, targeting over 200 million chronic pain patients in China. The product employs hot-melt adhesive transdermal technology, reducing patch thickness by 56% and weight by 75%, while achieving 13 times the transdermal delivery rate of conventional products. It was also granted a four-year data protection period.

Additionally, on August 4, the company's BCL-2 inhibitor TQB3909 NDA was accepted by CDE for treatment of chronic lymphocytic leukemia, having entered priority review in July. On August 3, ADC drug TQB2102 received its third breakthrough therapy designation for HER2-low metastatic breast cancer, reinforcing its broad oncology potential. The board is also scheduled to review interim results and dividends on August 19.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)